Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.

ABSTRACT:

Background

Prevention of IgE-binding to cellular IgE-receptors by anti-IgE (Omalizumab) is clinically effective in allergic asthma, but limited by IgE threshold-levels. To overcome this limitation, we developed a single-use IgE immunoadsorber column (IgEnio). IgEnio is based on a recombinant, IgE-specific antibody fragment and can be used for the specific extracorporeal desorption of IgE.

Objective

To study safety and efficacy of IgEnio regarding the selective depletion of IgE in a randomized, open-label, controlled pilot trial in patients with allergic asthma and to investigate if IgEnio can bind IgE-Omalizumab immune complexes.

Methods

Fifteen subjects were enrolled and randomly assigned to the treatment group (n=10) or to the control group (n=5). Immunoadsorption w

SUBMITTER: Lupinek C 

PROVIDER: S-EPMC5360571 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature